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Abstract
Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) is a 
pandemic with major implications across the world. One of the most frequent 
causes of death from SARS-CoV-2 is fatal pneumonia from coronavirus 
disease 2019 (COVID-19), which is associated with the development of acute 
respiratory distress syndrome (ARDS). To date (as of April 2 2020), other than
supportive measures, there are no efficient therapeutic options for COVID-19 
related ARDS, though the Food and Drug Administration recently granted 
emergency authorization for the use hydroxychoroquine/chloroquine for this 
indication (which is usually given with azithromycin). Although the 
pathogenesis for ARDS is under investigation, one of the major culprits is 
considered to be cytokine storm, especially from interleukin 6 (IL-6) release. 
Herein, we review potential use of IL-6 inhibitors, several of which are 
approved for other disease conditions, as potential novel treatment for the 
management of COVID-19 related ARDS. 
Introduction
As of April 2, 2020, the novel betacoronavirus--severe acute respiratory 
syndrome-coronavirus-2 (SARS-CoV-2)--has led to 1,011,064 detected 
infected cases and has been found in about  ~53,000 patients who have died 
throughout the worldwide [1]. Genome sequencing indicated that SARS-CoV2 
has about 80% structural similarity to SARS-CoV (first reported in 2003) and 
is ~96% identical at the whole-genome level to a bat coronavirus [2]. Another
betacoronavirus, Middle East Respiratory Syndrome virus, is reported to be 
more remotely associated with SARS-CoV-2 (~50% similarity), and is also a 
bat coronavirus [3]. Person-to-person spread of SARS-CoV-2 is considered to 
occur mainly by respiratory droplets (similar to influenza). 
The range of symptoms due to SARS-CoV-2 varies from no or mild 
symptoms without respiratory complications (at least 80% of patients), to 
severe symptoms (with dyspnea and hypoxia, or greater than 50% of lung 
involvement) and critical cases (with respiratory failure, shock and multi-
organ dysfunction).  The overall case fatality rate (CFR) was ~2-3% according
to the Chinese Center for Disease Control and Prevention [4]; overall case 
fatality may be lower in the USA and has been estimated to be ~0.1% by 
Fauci and colleagues in his recent New England Journal of Medicine editorial
[5]. The difficulty in estimating CFR is mainly due to the fact that large 
numbers of people remain untested with either the polymerase chain 
reaction test that detects acute infection or, even more importantly, the 
antibody test that detects past infection and immunity; hence the 
denominator of cases is unknown.   
Underlying disease conditions such as cardiovascular disease, 
diabetes, chronic respiratory disease and cancer as well as being elderly, 
especially among those over 80 years of age, has been linked to significantly 
higher fatality rates; however, again, the actual CFR is unclear because the 
denominator of infected cases with these comorbidities is unknown.  Only 
about 1% of deaths occur in younger people and/or those of any age without 
comorbidities [6-8]. One of the major causes of death from SARS-CoV-2 is 
fatal pneumonia from coronavirus disease 2019 (COVID-19), which can lead 
to the development of acute respiratory distress syndrome (ARDS). The 
management of ARDS is mainly supportive, including hemodynamic 
monitoring, nutritional support, and oxygenation. In severe cases, 
management with mechanical ventilation or extracorporeal membrane 
oxygenation have been reported [9].  There have been recent studies, albeit 
poorly controlled, showing effectiveness for hydroxychloroquine combined 
with azithromycin [10], and the US Food and Drug Administration just gave 
emergency authorization to their use to combat COVID-19 [11]. 
The pathogenesis of SARS-CoV-2-related ARDS is still under active 
investigation. However, it has been implied that the viral infection can lead to
an excessive immune reaction (cytokine storm), which is associated with 
extensive tissue and organ damage. One of the major culprits in cytokine 
storm is considered to be the burst of production of the cytokine interleukin 6
(IL-6) by activated leukocytes [12]. IL-6 promotes the differentiation of B 
lymphocytes and also stimulates the synthesis of acute phase proteins and is 
hence implicated in the pathogenesis of acute systemic inflammatory 
syndrome with fever and multiple organ dysfunction (also known as cytokine 
release syndrome) [12, 13].  Indeed, preliminary reports suggest that high IL-
6 levels were closely related with high serum SARS-CoV-2 nucleic acid level, 
and that IL-6 levels were significantly elevated among critically ill patients 
(10-fold higher than in those not in critical condition) [14]. Herein, we review 
IL-6 as a potential therapeutic target for the management of SARS-CoV2 
infection. 
IL-6 and its biologic role:  IL-6 is a pleiotropic cytokine that contributes to 
the physiology of almost every organ system; it plays a vital role in the 
response to infection as well as injury, and participates in hematopoiesis, 
immunity, and inflammation [15].  In regard to immune effects, IL‐6 is a 
potent and essential factor for the normal development and function of both 
B and T lymphocytes.  IL‐6 is also a central regulator of the acute‐phase 
response in the liver and fever. IL-6 therefore appears to be a mediator of 
human conditions that involve prolonged inflammation.  
Rapid synthesis of IL-6 contributes to host defense during infection and
tissue injury, but excess IL-6 production and/or dysregulation of IL-6 receptor 
signaling mediates disease pathology. Indeed, aberrant expression of IL-6 is 
implicated in diverse human diseases, most notably infectious, inflammatory 
and autoimmune disorders, cancer, coronary artery and neurologic disease, 
and pregnancy problems [15]. 
IL-6 and its receptor system:  IL‐6 was cloned first by Hirano et al., in 
1986 [16]. IL‐6 gene transcription is induced in many different normal tissues 
in response to stimuli, e.g., DNA and RNA virus infection, lipopolysaccharide, 
serum, bacterial endotoxin, inflammatory cytokines such as tumor necrosis 
factor (TNF), IL‐1, and platelet‐derived growth factor,  and the interferons 
(IFNs) [15]. 
IL-6 signals through a cell-surface type I cytokine receptor consisting of
the ligand-binding IL-6 receptor alpha (IL-6Rα) chain (CD126) and the signal-
transducing component gp130 (also known as IL-6 signal transducer or 
CD130); the latter is the common signal transducer for several cytokines 
including, but not limited to, leukemia inhibitory factor, oncostatin and IL-11, 
and is expressed in protean tissues.  In contrast, the expression of CD126 is 
limited to specific tissues. As IL-6 interacts with its receptor, it prompts the 
gp130 and IL-6R proteins to form a complex, thus activating the receptor. 
These complexes bring together the intracellular regions of gp130 to trigger a
signal transduction cascade through certain transcription factors such as JAKs
and STATs. In addition to the membrane-bound receptor, a soluble form of IL-
6R (sIL-6R) exists; sIL-6R has agonist activity.  The complex of IL-6 and sIL-6R
can bind to gp130 on cells that do not express the IL-6R and, therefore, these
cells may respond to IL-6 even in the absence of IL-6R [17]. 
Therapeutic implications of IL-6:  Suppressing IL-6 is an innovative 
therapeutic strategy in several diseases and has salutary effects. In cancer, 
high levels of circulating IL-6 are observed in almost every type of tumor 
studied and predict a poor outcome [18-20]. Furthermore, elevated IL-6 
levels are strongly associated with several of the striking phenotypic features
of cancer. 
Inflammatory diseases may also be triggered by IL-6.   Therapeutic 
agents targeting the IL-6 axis are effective in rheumatoid arthritis and 
Castleman disease (a rare disorder that involves an overgrowth of lymph 
nodes) and specific IL-6 inhibitory agents are approved for these conditions 
(Table 1) [21-24]. Applications are being extended to other settings of acute 
and chronic inflammation.  Most recently, anti-IL-6 agents are being explored 
for activity in patients afflicted with corona virus (SARS-CoV-2) [25]. 
Repurposing IL-6 inhibitors for corona virus (SARS-CoV-2; COVID-19)
infection
Considering that IL-6 that may play a critical role in driving the 
hyperactive inflammatory response in the lungs amongst critically ill patients 
with coronavirus disease 2019 (COVID-19), the respiratory illness that is 
produced by SARS-CoV-2 infection, multiple Food and Drug Administration 
(FDA) approved IL-6 inhibitors are now being repurposed to be used for the 
management of SARS-CoV-2 infection.
As an example, tocilizumab (FDA-approved anti-IL-6 monoclonal 
antibody), which is used for conditions including rheumatoid arthritis, giant 
cell arteritis and cytokine release syndrome from chimeric antigen receptor T-
cell therapy, is produced by Genentech/Roche and is being tested among 
patients with severe COVID-19 pneumonia [26]. This study will be an 
important follow up on the anecdotal report from the Chinese group wherein 
they successfully used tocilizumab for patients with severe-critical COVID-19 
infection [27].  They showed improvement in the majority of patients in terms
of oxygen intake (75% [15/20]) and CT of chest findings (95% [19/20]) as well
as a decrease in serum C-reactive protein (84% [16/19]). Most patients (95% 
[19/20]) were discharged within an average of 13.5 days after the tocilizumab
was started [27]. 
EUSA Pharma also announced a study of siltuximab (IL-6 targeted 
monoclonal antibody approved by the Food and Drug Administration [FDA] 
for Castleman disease) [22-24] for patients with COVID-19 with serious 
respiratory complications (“Siltuximab In Serious COVID -19; SISCO Study, 
clinicaltrials.gov [NCT04322188]”) [28].  Finally, Regeneron Pharmaceuticals 
and Sanofi launched a trial with sarilumab (IL-6 receptor antagonist approved
by the FDA for rheumatoid arthritis) for treatment of severe COVID-19 
(clinicaltrials.gov, NCT04315298) [29]. 
The studies using IL-6 inhibitors, along with other clinical trials 
examining hydroxychloroquine and azithromycin (clinicaltrial.gov: 
NCT04321278, NCT04322396 and NCT04322123), antivirals such as 
remdesivir (NCT04292899 , NCT04292730), and recovered patient plasma
[30], have been activated in record speed, along with intense efforts to 
examine other drugs and develop a vaccine, in order to combat COVID-19.  
Indeed, the model of rapid clinical trial activation and clinical development of 
treatments spurred by the SARS-CoV-2 and assisted by the FDA, may be a 
long-lasting positive legacy of this pandemic and, if successful, may be 
exploited to overcome other diseases such as cancer as well.
Table 1:  Examples of IL-6 inhibitory molecules, their FDA-approved indications, and plans for testing 
against COVID-19.
Drug Generic 
Name
Siltuximab Tocilizumab Sarilumab
Drug Trade 
name
Sylvant Actemra Kevzara
Company Janssen
EUSA
Genentech/ Roche Sanofi-Regeneron
Mechanism Anti-IL6 Anti-IL6 receptor Anti-IL6 receptor
Indication Castleman Disease Rheumatoid arthritis
Giant cell arteritis
Polyarticular juvenile idiopathic arthritis 
Systemic juvenile idiopathic arthritis 
Chimeric antigen receptor T cell-induced
cytokine release syndrome
Rheumatoid arthritis
Comment re 
trials launched 
for Covid-19
One study recruiting 
as of 3/30/2020:
Observational case-
control study 
(NCT04322188).
Three studies recruiting as of 3/30/2020:
Phase II study for COVID-19 pneumonia 
(NCT04317092)
Tocilizumab vs. Continuous Renal 
Replacement Therapy among COVID-19 
cytokine release syndrome 
(NCT04306705).
Patients randomized to combination with
favipiravir and tocilizumab or either of 
the drug (NCT04310228). 
One study recruiting as of 
3/30/2020:
Evaluation of efficacy and 
safety of sarilumab in 
hospitalized patients with 
COVID-19.3  (NCT04315298). 
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